UCLA's Jonsson Comprehensive Cancer Center

Site:	UCLA's Jonsson Comprehensive Cancer Center	Go to their website
Address:	10945 Le Conte Ave.
City:	Los Angeles
State:	CA
Zip:	90095
Country:	USA

17 trials at this site

Phase	Trial	Trial Status	Site Status [desc]	Drug	NCT#
2	Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) (Novartis CSTI571BUS282)	Completed	Not yet activated	Imatinib	NCT00867113
3	Efficacy and Safety of AMN107 Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib (ENEST)	Completed	Closed	Nilotinib	NCT00471328
3	Study of IPI-504 in GIST patients following failure of at least imatinib and sunitinib	Terminated	Closed	IPI-504	NCT00688766
3	SU011248 in Treating Patients With Malignant Gastrointestinal Stromal Tumor	Completed	Closed	Sunitinib	NCT00085618
3	Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients (ENESTg1)	Completed	Closed	Nilotinib or Imatinib	NCT00785785
3	Efficacy and Safety of AMN107 Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib - Extension	Completed	Closed	Nilotinib	NCT00488150
3	Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)	Active, not recruiting	Closed	QINLOCK Ripretinib DCC-2618	NCT03353753
2	A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)	Completed	Closed	STA-9090	NCT01039519
2	Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01068769
2	Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors	Completed	Closed	Imatinib + RAD001	NCT01275222
2	Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery	Active, not recruiting	Closed	Nivolumab + Ipilimumab	NCT02880020
1	Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies	Ongoing, but not recruiting	Closed	XL228	NCT00526838
1	Safety Study of PLX108-01 in Patients With Solid Tumors	Ongoing, but not recruiting	Closed	PLX3397 (PLX108-01)	NCT01004861
1	A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients	Ongoing, but not recruiting	Closed	BKM120 + GSK1120212	NCT01155453
1	Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer	Terminated	Closed	PF-052112384 + PD-0325901 OR PF-052112384 + Irinotecan	NCT01347866
1	Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors	Ongoing, but not recruiting	Closed	STA-9090	NCT00688116
1	A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors	Ongoing, but not recruiting	Closed	PLX3397 + Pembrolizumab	NCT02452424